Beta-thalassemia and Microparticles

Public Assistance-Hospitals of Marseille (AP-HM)

Status

Completed

Conditions

Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes

Thalassemia Intermedia (TI)

Thalassemia Major (TM)

Treatments

Other: Physiopathology

Study type

Interventional

Funder types

Other

Identifiers

NCT01284738

2009-18

2010-A00198-31

Details and patient eligibility

About

The results will allow us to evaluate the role of MP in the thrombo-embolic risk observed in thalassemic patients and to underline a possible difference between TM and TI. The in vitro and in vivo study of MP in erythrocytes concentrates is a new approach to explore the consequence of transfusion in polytransfused patients. Finally, the identification of a possible relationship between the oxidative stress and the production of MP may lead to the development of specific therapeutical approaches

Full description

Microparticles (MP) are intact vesicles derived from cell membranes which arise mainly through cell membrane activation processes and from apoptosis. MP originating from platelets, endothelial cells and monocytes have been most extensively studied, though similar particles can arise from red cells and granulocytes. The ability to form microparticles is an essential part of physiological coagulation.However, MP may play an important procoagulant role in several diseases including sickle cell disease, and paroxysmal nocturnal haemoglobinuria (PNH).

Several studies reported the presence of MP in TI and their potential role in the hypercoagulable state. The investigators propose in this study to investigate the presence and origin of MP in TM patients.

Enrollment

33 patients

Sex

All

Ages

15+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient recorded in the national register of the patients attained by beta-thalassemia (TI) or (TM)
Patient monitoring in one of 5 recruiters centers
Patient more than 15 years
Patient consented and informed

Exclusion criteria